<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02183805</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-004</org_study_id>
    <nct_id>NCT02183805</nct_id>
  </id_info>
  <brief_title>Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer</brief_title>
  <official_title>Phase II Study of Chemotherapy Followed by Peripheral Stem Cell Transplantation as First Line Therapy for Metastatic Triple-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop&#xD;
      growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow&#xD;
      the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To explore the progression-free survival of patients with metastatic triple-negative breast&#xD;
      cancer treated with peripheral blood stem cell transplant (PBSCT) followed by high dose&#xD;
      chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty accruing subjects the study accrual was closed&#xD;
  </why_stopped>
  <start_date type="Actual">June 17, 2014</start_date>
  <completion_date type="Actual">December 15, 2020</completion_date>
  <primary_completion_date type="Actual">December 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free Survival</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Carcinoma Breast Stage IV</condition>
  <arm_group>
    <arm_group_label>Metastatic triple negative breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abraxane,Cyclophosphamide,Carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane,Cyclophosphamide,Carboplatin</intervention_name>
    <description>High dose chemotherapy: Abraxane, Cyclophosphamide, Carboplatin</description>
    <arm_group_label>Metastatic triple negative breast cancer</arm_group_label>
    <other_name>Abraxane 800 mg/m2</other_name>
    <other_name>Cyclophosphamide 3g/m2</other_name>
    <other_name>Carboplatin 800 mg/m2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0 or 1.&#xD;
&#xD;
          -  Histologically or cytologically proven diagnosis of breast cancer with evidence of&#xD;
             locally recurrent or metastatic disease.&#xD;
&#xD;
          -  Documentation of estrogen and progestin receptor (ER/PR) negative status and HER2/neu&#xD;
             receptor negative status (ie, FISH negative or immunohistochemistry 0 or +1).&#xD;
&#xD;
          -  Obtained complete response or Good partial response after first line chemotherapy.&#xD;
&#xD;
          -  Normal organ function required prior to study entry.&#xD;
&#xD;
          -  Willingness to comply with treatment plans and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled central nervous system (CNS) involvement with disease&#xD;
&#xD;
          -  Fertile women unwilling to use contraceptive techniques during treatment&#xD;
&#xD;
          -  Females who are pregnant&#xD;
&#xD;
          -  Organ dysfunction.&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhong-Yu Yuan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 1, 2014</study_first_submitted>
  <study_first_submitted_qc>July 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 18, 2021</last_update_submitted>
  <last_update_submitted_qc>July 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhong-yu Yuan</investigator_full_name>
    <investigator_title>Sun Yat-sen University Cancer Center</investigator_title>
  </responsible_party>
  <keyword>triple negative breast cancer</keyword>
  <keyword>autologous hematopoietic stem-cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

